May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Predictive Validity of the Glaucoma Treatment Compliance Assessment Tool
Author Affiliations & Notes
  • S. L. Mansberger
    Devers Eye Institute, Portland, Oregon
  • T. M. McClure
    Devers Eye Institute, Portland, Oregon
  • I. L. Swanson
    Devers Eye Institute, Portland, Oregon
  • W. E. Lambert
    Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon
  • G. A. Cioffi
    Devers Eye Institute, Portland, Oregon
  • Footnotes
    Commercial Relationships  S.L. Mansberger, Alcon, R; Allergan, R; Pfizer, R; T.M. McClure, None; I.L. Swanson, None; W.E. Lambert, None; G.A. Cioffi, Alcon, R; Allergan, R; Pfizer, R.
  • Footnotes
    Support  American Glaucoma Society (SLM); Alcon (SLM); NEI 5K23EY015501-01
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5057. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. L. Mansberger, T. M. McClure, I. L. Swanson, W. E. Lambert, G. A. Cioffi; Predictive Validity of the Glaucoma Treatment Compliance Assessment Tool. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5057. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if the Glaucoma Treatment Compliance Assessment tool (GTCAT), a survey based on the Health Belief Model (HBM), is associated with objective and subjective measures of compliance in glaucoma patients.

Methods: : Fifty-eight patients from a tertiary glaucoma practice participated in this cross-sectional survey. All patients were using travoprost and the Travatan Dosing Aid. We used a subjective measure: S1- the number of days missed in the last month, and three objective measures of compliance (O1-the proportion of days that the patient administered the drop within 3 hours of the designated time and used the appropriate number of drops; O2- the proportion of days that the patient administered the drop within 3 hours of the designated time; and O3- the proportion of days that the patient administered the drop within 6 hours of the designated time). We used parametric and nonparametric models to identify significant associations between compliance and survey questions.

Results: : Patients reported a mean 1.79 +/- 2.6 (range 0-14) days without using medication with a S1 measure of 94%. The proportion of days compliant by measures O1, O2, and O3 were 70%, 80%, 86%, respectively. Age, ethnicity, and the HBM constructs of knowledge, susceptibility, benefits, and barriers were significantly associated with one or more of the compliance measures (p<0.05).

Conclusions: : Patients overestimated compliance in comparison to objective measures. The survey has predictive validity with objective and subjective measures of compliance. We need further studies before recommending clinical use of the GTCAT.

Keywords: clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×